Surface effects on the crystallization of ritonavir glass

Journal of Pharmaceutical Sciences

Volumn 104, Issue 1, 2015, Pages 276-279

  Kawakami, Kohsaku ^a  

^a NATIONAL INSTITUTE FOR MATERIALS SCIENCE   (Japan)

Author keywords

Amorphous; Crystallization; Glass transition; Physical stability; Surface effect; Thermal analysis

Indexed keywords

RITONAVIR; WATER; CYTOCHROME P450 3A INHIBITOR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR;

ARTICLE; ATMOSPHERE; CRYSTALLIZATION; FREEZE DRYING; GLASS TRANSITION TEMPERATURE; STORAGE; ALGORITHM; CHEMICAL STRUCTURE; CHEMISTRY; COMPARATIVE STUDY; CONFORMATION; DRUG STABILITY; ENERGY TRANSFER; KINETICS; PHASE TRANSITION; POROSITY; POWDER DIFFRACTION; SCANNING ELECTRON MICROSCOPY; SURFACE PROPERTY;

ALGORITHMS; CRYSTALLIZATION; CYTOCHROME P-450 CYP3A INHIBITORS; DRUG STABILITY; ENERGY TRANSFER; FREEZE DRYING; HIV PROTEASE INHIBITORS; KINETICS; MICROSCOPY, ELECTRON, SCANNING; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PHASE TRANSITION; POROSITY; POWDER DIFFRACTION; RITONAVIR; SURFACE PROPERTIES; WATER;

EID: 84919784893     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.24229     Document Type: Article

References (15)

1. Serajuddin A T M. 1999. Solid dispersion of poorly water-soluble drugs: Early promises, subsequent problems, and recent breakthroughs. J Pharm Sci 88:1058-1066.
2. Yu L. 2001. Amorphous pharmaceutical solids: Preparation, characterization and stabilization. Adv Drug Deliv Rev 48:27-42.
3. Kawakami K. 2009. Current status of amorphous formulation and other special dosage forms as formulations for early clinical phases. J Pharm Sci 98:2875-2885.
4. Kawakami K. 2012. Modification of physicochemical characteristics of active pharmaceutical ingredients and application of supersaturatable dosage forms for improving bioavailability of poorly absorbed drugs. Adv Drug Deliv Rev 64:480-495.
5. Bhugra C, Pikal MJ. 2008. Role of thermodynamic, molecular, and kinetic factors in crystallization from the amorphous state. J Pharm Sci 97:1329-1349.
6. Kawakami K, Harada T, Miura K, Yoshihashi Y, Yonemochi E, Terada K, Moriyama H. 2014. Relationship between crystallization tendencies during cooling from melt and isothermal storage: Toward a general understanding of physical stability of pharmaceutical glasses. Mol Pharm 11:1835-1843.
7. Crowley KJ, Zografi G. 2003. The effect of low concentrations of molecularly dispersed poly (vinylpyrrolidone) on indomethacin crystallization from the amorphous state. Pharm Res 20:1417-1422.
8. g. Pharm Res 23:2350-2355.
9. Wu T, Sun Y, Li N, de Villiers MM, Yu L. 2007. Inhibiting surface crystallization of amorphous indomethacin by nanocoating. Langmuir 23:5148-5153.
10. Kawakami K, Numa T, Ida Y. 2001. Assessment of amorphous content by microcalorimetry. J Pharm Sci 91:417-423.
11. Kawakami K, Miyoshi K, Tamura N, Yamaguchi T, Ida Y. 2006. Crystallization of sucrose glass under ambient conditions: Evaluation of crystallization rate and unusual melting behavior of resultant crystals. J Pharm Sci 95:1354-1363.
12. Heljo VP, Nordberg A, Tenho M, Virtanen T, Jouppila K, Salonen J, Maunu SL, Juppo AM. 2012. The effect of water plasticization on the molecular mobility and crystallization tendency of amorphous disaccharides. Pharm Res 29:2684-2697.
13. Matsumoto T, Zografi G. 1999. Physical properties of solid molecular dispersions of indomethacin with poly (vinylpyrrolidone) and poly (vinylpyrrolidone-co-vinylacetate) in relation to indomethacin crystallization. Pharm Res 16:1722-1728.
14. Otsuka M, Matsuda Y. 1994. The effect of humidity on hydration kinetics of mixtures of nitrofurantoin anhydrate and diluents. Chem Pharm Bull 42:156-159.
15. Airaksinen S, Luukkonen P, Jorgensen A, Karjalainen M, Rantanen J, Yliruusi J. 2003. Effects of excipients on hydrate formation in wet masses containing theophylline. J Pharm Sci 92:516-528.